|
|
Effect of Hematodialysis Combined with Hemoperfusion on Insulin Resistance and Nutritional Status of Patients with End-Stage Diabetic Nephropathy |
Antony Raine, Daniel Cordonnier*, Eberhard Ritz |
Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA |
|
|
Abstract Objective: To explore the effect of hematodialysis (HD) combined with hemoperfusion (HP) on the insulin resistance (IR) and nutritional status of patients with end-stage diabetic nephropathy (ESDN).
Methods: Eighty-six patients with ESDN were randomly divided into group A (n=28), group B (n=30) and group C (n=28), and another 24 healthy volunteers were selected as control group. Groups A, B and C were respectively treated with routine HD, HD combined with hemodiafiltration (HDF) as well as HD combined with HP. The levels of C-reactive protein (CRP), tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) as well as the changes of urea nitrogen(Scr), fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (Homa-IR), hemoglobin (Hb), albumin (Alb) and body mass index (BMI) were compared among groups before and 12 weeks after treatment. (BUN), creatinine
Results: 12 weeks after treatment, the levels of CRP, TNF-α and IL-6 in group A did not change obviously, whereas those in groups B and C decreased dramatically when compared with treatment before (P<0.05 or P<0.01), in which the decreased range in group C was the most significant, but it was still higher than in control group (P<0.01). There was no statistical significance among three groups with regard to the levels of BUN and Scr before and 12 weeks after treatment (P>0.05). Compared with treatment before, FBG and FINS levels as well as Homa-IR reduced (P<0.05 or P<0.01), Hb, Alb and BMI elevated markedly in group C 12 weeks after treatment (P<0.01), while those in groups A and B did not change conspicuously (P>0.05). FBG, FINS and Homa-IR were all lower, but Hb, Alb and BMI were markedly higher in group C than in groups A and B 12 weeks after treatment, and significant differences were shown (P<0.05 or P<0.01).
Conclusion: HD combined with HP can effectively remove the mid- and macro-molecular inflammatory mediators in the patients with ESDN, alleviate IR and ameliorate the nutritional status to reduce the incidence of malnutrition.
|
|
Corresponding Authors:
Daniel Cordonnier, E-mail: danielcord@sina.com
|
|
|
|
2 Tang FP, Liu T. Hemoperfusion joint compound α keto acids in maintenance hemodialysis patients and to improve the nutritional status of micro-inflammation effect. Chinese Med Sci, 2013, 3(15): 168-70.
3 Bouhabel A, Saadi N, Bendjeddou J, et al. Diabetic nephropathy in hemodialysis patients in Constantine, Algeria. Saudi J Kidney Dis Transpl, 2015, 26(1): 139-40.
4 Xie JL, Nie QQ, Li XF. Effect of hematodialysis combined with hemoperfusion on the nutritional and micro-inflammatory state in the patients with diabetic nephropathy. J Hainan Med Coll, 2015, doi: 10.13210/j.cnki.jhmu.20150515.005.
6 Couchoud C, Savoye E, Frimat L, et al. Variability in case mix and peritoneal dialysis selection in fifty-nine French districts. Perit Dial Int, 2008, 28: 509-17.
8 Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation indevelopment of diabetes and its complications. J Clin Endocrinol Metab, 2009, 94(9): 3171-82.
10 Ghannoum M, Bouchard J, Nolin TD, et al. Hemoperfusion for the treatment of poisoning: technology, determinants of poison clearance, and application in clinical practice. Semin Dial, 2014, 27(4): 350-61.
13 Zhang Y, Mei CL, Rong S, et al. Effect of the combination of hemodialysis and hemoperfusion on clearing advanced glycation end products: A prospective, randomized, two-stage crossover trial in patients under maintenance hemodialysis. Blood Purif, 2015, 40(2): 127-32. |
[1] |
TAN Mi-duo. Research Progress of Translational Medicine in Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 86-91. |
[2] |
SHEN Bo, LU Jian-wei, ZHANG Yan, WU Yuan, YUAN Yuan, FENG Ji-feng. Research Progress of MicroRNAs in Gastric Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 71-79. |
[3] |
Lukas Gietz, Benjamin Mayer. A Resampling Approach for Sample Size Estimation in Animal Experiments[J]. Journal of International Translational Medicine, 2017, 5(2): 53-62. |
[4] |
QIAN Ting, HUANG Xin-en. Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 63-66. |
[5] |
MAO Xiao-dong, ZHE Yi, CHEN Ya-jun, LIU Kang-sheng. Detection of Serum Anti-Müllerian Hormone Level for Women of Reproductive Age: A Cross-Sectional Study[J]. Journal of International Translational Medicine, 2017, 5(2): 67-70. |
[6] |
LIU Yong-jun, ZHOU Yan. Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy[J]. Journal of International Translational Medicine, 2017, 5(2): 80-85. |
|
|
|
|